Routine Gyn/ Female Patient Health Maintenance Flashcards
A pt comes in with no concerning PMH,complaints, or abnormal bleeding. Ultrasound shows an anechoic mass with no septae with thin walls as shown in the photo. What is recommended for this patient?
F/u exam.
Her findings are suggestive of a benign ovarian cyst. Management consists of follow-up examinations to monitor possible growth of the cyst, of which the majority resolve spontaneously. Treatment is only required if complications occur (e.g., ovarian torsion, ovarian cyst rupture).
What signs and findings would you observe with a patient in TSS-1?
-leukocytosis
-fever
-tachycardia
-low blood pressure
-along with a diffuse, erythematous rash
-skin peeling
-acute kidney injury (look at Cr and urea nitrogen)
-thrombocytopenia (low platelets!)
What organism causes TSS-1?
Staph a
For a self-palpated breast lumps in women, when do we recommend US over mammography as our next steps?
US is for women younger than 30 yo, for women over 40 yo we recommend mammography
A small, concentric, hypoechoic myometrial mass in a nulliparous woman of reproductive age is suggestive of
uterine leiomyoma
For a female of reproductive age presenting with signs of PCOS with no desire for children at this time, what is the first line therapy for her?
Combo OCPs
A combination oral contraceptive pill (COCP) containing ethinylestradiol and progestin is the first-line pharmacotherapy for patients with PCOS who currently do not wish to conceive. COCPs help regulate the menstrual cycle and, because of antiandrogenic effects, relieve symptoms of hyperandrogenism. In addition, progestin decreases the risk of endometrial hyperplasia and cancer, which are possible complications of PCOS (due to the increased levels of estrogen from aromatization of androgens). Besides pharmacotherapy, weight loss is the mainstay of treatment because obesity and the associated insulin resistance play an important role in the pathophysiology of PCOS.
_______________ a selective estrogen receptor modulator (SERM), is the drug of choice for osteoporosis in postmenopausal women who are at an increased risk of developing breast cancer (in this case, the history of breast cancer at a young age in a first-degree relative and nulliparity increase this patient’s risk). An adverse effect that is due to its estrogenic activity should be considered.
Raloxifene
This mediation prevents bone resorption by acting as an agonist on estrogen receptors in the bone. At the same time, it acts as an estrogen antagonist in the breast and endometrium.
raloxifene
What is the most severe adverse effects of raloxifene?
Thromboembolic events
Combo CHC’s decrease risk of what cancers?
COCPs can decrease the risk of ovarian cancer, possibly through reduced cell proliferation within the ovaries and fallopian tubes. They also reduce the risk of endometrial cancer; the progestin contained therein opposes estrogen-driven endometrial hyperplasia, which reduces the risk for the development of type 1 endometrial cancer.
What cancer risk is contraindicative for COCPs?
Combined oral contraceptives do not reduce the risk for breast cancer. However, there is controversy as to whether current OCPs actually increase the risk for breast cancer, and therefore should be used with caution in a patient with a high risk for breast cancer development (e.g., BRCA mutations).
COCP’s may also increase the incidence of hepatic adenomas.
_________________________is a common benign phenomenon in women of reproductive age that is caused by physiologic enlargement and rupture of the follicular cyst during ovulation, which leads to the release of small amount of intraperitoneal fluid and subsequent peritoneal irritation. The pain is self-limited and usually subsides within a few hours to two days.
Mittelschmerz
What is our firstline tx for mittelschmerz?
Reassurance and NSAIDs
What are the cardiovascular side effects of COCPs?
Hypertension and thromboembolism. Estrogen-containing oral contraceptives may also cause hyperlipidemia and a mild increase in the incidence of hepatic adenomas.
For women ages 30 to 65, what is the screening recommendations for cytology and high risk HPC testing (“co-testing)?
Co-testing every 5 years assuming that their last pap/cotest was clear, high risk HPV testing along every 5 years or cytology alone every 3 years is also acceptable